Successful management of lamotrigine-associated skin rashes in an adolescent girl with autism and bipolar disorder
Bu makale için 30 Eylül 2025 tarihinde bir düzeltme yayımlandı. https://dergipark.org.tr/tr/pub/cumj/article/1790562
Öz
Lamotrigine, an antiepileptic class drug, is an agent that can be used as a mood stabilizer in children and adolescents and skin rashes as a side effect are seen. Rarely, Stevens Johnson Syndrome may develop with skin rashes that may be mortal accompanied by systemic symptoms. In this paper, lamotrigine was started as a mood stabilizer in addition to the current olanzapine treatment in an 18 years old adolescent girl with autism spectrum disorderand bipolar disorder type 2. After the dose was increased, erythematous acneiform rash developed on the 10th day. Then, lamotrigine was discontinued and skin rashes regressed. Slowly titrating lamotrigine dose, noticing skin rashes on treatment and be able to distunguish bening and malign rash are so helpful for clinicians. An 18 years old adolescent girl who was followed up with the diagnosis of autism spectrum disorder and bipolar disorder was started on lamotrigine as a mood stabilizer in addition to the current olanzapine treatment. On the 10th day of treatment, erythematous acneiform skin rashes appeared on the face. After the dermatology consultation response, the drug was discontinued and the skin rashes regressed within 1 week.
The fact that the skin rashes appeared in the head-neck region, were mildly painful, tended to coalesce, and resolved when the drug was discontinued, suggested that might be malign rash. The absence of systemic symptoms, intact blood values and no additional treatment is required, suggested that might be benign rash. Further studies are needed on the use of lamotrigine in children and adolescents with autism spectrum disorder.
Anahtar Kelimeler
autism spectrum disorder, lamotrigine, skin rashes
Proje Numarası
1
Kaynakça
- Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993;43:2284-91.
- Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013;74:675-84.
- Guldiken G, Karayagmurlu A, Kucukgergin C, Coskun M. VEGF, IGF-1 and FGF-2 serum levels in children and adolescents with autism spectrum disorder with and without bipolar disorder. J Autism Dev Disord. 2024;54:3854-62.
- Uludag Gedik C, Karayagmurlu A, Kucukgergin C, Bingul I, Coskun M. Peripheral markers of nitrosative stress in children with autism spectrum disorder and bipolar disorder comorbidity during euthymic phase. Res Autism Spectr Disord. 2023;109:102259.
- Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney JA. Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19:75-82.
- Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry. 2004;65:1720-2.
- Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure. 2000;9:282-6.
- Sassolas B, Haddad C, Dunant A, Allanore LV, Roujeau JC. Evolution in europe of the causes of SJS/NET linked to high risk medicines. Analysis over 10 years.Ann Dermatol Venereol. 2011;138:89-92.
- Lorberg B, Youssef NA, Bhagwagar Z. Lamotrigine-associated rash: to rechallenge or not to rechallenge?. Int J Neuropsychopharmacol. 2009;12:257-65.
